<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Iran J Pharm Res</journal-id><journal-id journal-id-type="iso-abbrev">Iran J Pharm Res</journal-id><journal-id journal-id-type="publisher-id">IJPR</journal-id><journal-title-group><journal-title>Iranian Journal of Pharmaceutical Research : IJPR</journal-title></journal-title-group><issn pub-type="ppub">1735-0328</issn><issn pub-type="epub">1726-6890</issn><publisher><publisher-name>Shaheed Beheshti University of Medical Sciences</publisher-name><publisher-loc>Tehran, Iran</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24734084</article-id><article-id pub-id-type="pmc">3985259</article-id><article-id pub-id-type="publisher-id">ijpr-13-299</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Vaginal Versus Sublingual Misoprostol for Labor Induction at Term and Post Term: a Randomized Prospective Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ayati</surname><given-names>Sedigheh</given-names></name><xref ref-type="aff" rid="affa">a</xref></contrib><contrib contrib-type="author"><name><surname>Vahidroodsari</surname><given-names>Fatemeh</given-names></name><xref ref-type="aff" rid="affa">a</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Farshidi</surname><given-names>Farnoosh</given-names></name><xref ref-type="aff" rid="affb">b</xref></contrib><contrib contrib-type="author"><name><surname>Shahabian</surname><given-names>Masoud</given-names></name><xref ref-type="aff" rid="affc">c</xref></contrib><contrib contrib-type="author"><name><surname>Afzal Aghaee</surname><given-names>Monavar</given-names></name><xref ref-type="aff" rid="affd">d</xref></contrib></contrib-group><aff id="affa"><label>a</label><italic>Women</italic>&#x01fbd;<italic>s Health Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran. </italic></aff><aff id="affb"><label>b</label><italic>Obstetrics Gynecologist, Mashhad University of Medical Sciences, Mashhad, Iran. </italic></aff><aff id="affc"><label>c</label><italic>Mashhad University of Medical Sciences, Cardio-Vascular Research Center, Mashhad, Iran. </italic></aff><aff id="affd"><label>d</label><italic>Department of Medicosocial, Biostatics Unit, Mashhad University of Medical Sciences, Mashhad, Iran.</italic></aff><author-notes><corresp id="cor1"><label>*</label>Corresponding author: 
E-mail: vahidroodsarif@mums.ac.ir
</corresp></author-notes><pub-date pub-type="ppub"><season>Winter</season><year>2014</year></pub-date><volume>13</volume><issue>1</issue><fpage>299</fpage><lpage>304</lpage><history><date date-type="received"><month>4</month><year>2012</year></date><date date-type="accepted"><month>11</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; 2014 by School of Pharmacy, Shaheed Beheshti University of Medical Sciences and Health Services</copyright-statement><license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>We want to compare the efficacy and safety of vaginal versus sublingual misoprostol for cervical ripening and induction of labor. This randomized clinical trial was performed on 140 women with medical or obstetric indications for labor induction. The patients were randomly divided into two groups: vaginal and sublingual administration of misoprostol. In first group, 25 &#x000b5;g misoprostol was placed in the posterior fornix of the vagina and second group received 25 &#x000b5;g misoprostol sublingually, every 6 hours for 24 h. Maternal and neonatal outcomes were analyzed. There was no significant difference in the demographic characteristics between two groups. The main indication for cesarean section in both groups was fetal distress, followed by absence of active labor progress. Evaluation of cesarean indication was not significantly different in two groups; including fetal distress, absence of active labor, uterine over activity and failure to progress. The maternal complication in sublingual group included residual placenta (2%), tachysystole (2%), vomiting (12%), atoni (3.3%) and abdominal pain (5.5%), although there was no significant difference between two groups. Sublingual misoprostol is as effective as vaginal misoprostol for induction of labor at term. However, sublingual misoprostol has the advantage of easy administration and may be more suitable than vaginal misoprostol. </p></abstract><kwd-group><title>Key Words</title><kwd>Induction of labor</kwd><kwd>Misoprostol</kwd><kwd>Vaginal</kwd><kwd>Sublingual</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p> Induction of labor is usually performed when the risks of continuing pregnancy are higher than the benefits of delivery (<xref rid="B1" ref-type="bibr">1</xref>-<xref rid="B3" ref-type="bibr">3</xref>). Undoubtedly, uterine cervical tissue ripening or its softening has a close relationship with success rate of delivery. </p><p>There are several effective methods for cervix ripening including mechanical with osmotic dilators (<xref rid="B4" ref-type="bibr">4</xref>) or balloon catheters (<xref rid="B5" ref-type="bibr">5</xref>), and biochemical with prostaglandins (<xref rid="B6" ref-type="bibr">6</xref>), antiprogestins (<xref rid="B7" ref-type="bibr">7</xref>), or nitric oxide donors (<xref rid="B8" ref-type="bibr">8</xref>). Among many proper methods for cervical ripening, there is still no agreement on which method is the best for labor induction of cases with unripe cervix. </p><p>Among prostaglandins, Misoprostol (PGE1) is widely used for &#x000ab;induction of labor&#x000bb; and cervical ripening (<xref rid="B9" ref-type="bibr">9</xref>-<xref rid="B11" ref-type="bibr">11</xref>). Cervical ripening occurs by the activation of prostaglandin E2 receptor. </p><p>The most effective therapy for peptic ulcer is still unknown and prompts people to make great efforts to find better and more modern natural or synthetic agents (<xref rid="B12" ref-type="bibr">12</xref>). The prostaglandin E1 analogue (Misoprostol), synthetic 15 deoxxy-16 hydroxy-16-methyl is administrated for peptic ulcers therapy (<xref rid="B9" ref-type="bibr">9</xref>) (suppressed prostaglandin) used for cervical ripening and labor induction as well. Due to finding the Misoprostol, a relatively cheap and stable substance at room temperature without need to refrigeration for storage, like the other prostaglandins, with good proven efficacies, recently it is frequently used in obstetrics and gynecology for termination of pregnancy, especially at third trimester (<xref rid="B13" ref-type="bibr">13</xref>). However, some major complications are reported after administration of high doses of misoprostol, likewise uterine hyperstimulation and rupture (<xref rid="B14" ref-type="bibr">14</xref>). Vaginal and sublingual misoprostol have a rapid onset action, due to their prolonged activity and bioavailability (<xref rid="B11" ref-type="bibr">11</xref>). A sublingual dose of 50 mg every 4 h in most of cases, induce vaginal delivery within 24 hours and compared to an equivalent oral dose, less oxytocin augmentation is required (<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>). However, the previous studies found few significant differences among the effectiveness of different doses of the Misoprostol, oral, vaginal or sublingual (<xref rid="B17" ref-type="bibr">17</xref>). So this study is performed to compare the efficacy and safety of vaginal versus sublingual misoprostol with four hours interval for six doses for cervical ripening and induction of labor.</p></sec><sec><title>Experimental</title><p>This randomized clinical trial was conducted on 140 pregnant women who were admitted at Department of Obstetrics, Mashhad University of Medical Sciences during September 2007 to March 2008. </p><p>Inclusion criteria were gestational age&#x0003e;37 weeks on the basis of last menstrual period (LMP) or ultra-sonography at first trimester, need to pregnancy termination due to fetal or maternal indication, Bishop score &#x0003c; 7, gestational diabetes mellitus, singleton pregnancy, reassuring fetal heart rate tracing, cephalic presentation, low-located placenta, and mild preeclampsia.</p><p>Any cases of hypersensitivity to prostaglandin, temperature &#x0003e; 38 &#x000b0;C, previous cesarean delivery or other uterine surgery, placenta previa, chorioamnionitis, vaginal bleeding, fetal distress, need to immediate delivery, macrosomy, and polyhydroamnios were excluded from the study. </p><p>The women were randomly divided into two groups: 50 cases in vaginal misoprostol group (group 1) and 90 cases in sublingual misoprostol group (group 2). The sample size was calculated with NCSS software (Power = 80%, Alpha = 0.05). The method of randomization was simple randomization. At first, all conditions of the study were completely explained for the women; if written informed consent was obtained, they were entered to the study. This study was approved by the Ethics Committee of Mashhad University of Medical Sciences. </p><p>After randomization, for women in group 1, 25 &#x000b5;g misoprostol was placed in the posterior fornix of the vagina; and women in group 2 received 25 &#x000b5;g misoprostol sublingually. In each group, if needed, prescription was repeated up to 6 doses every 4 hours and vaginal examination was performed every 4 hours (<xref rid="B18" ref-type="bibr">18</xref>); if uterine contractions did not begin, the patient received another dose. In the presence of spontaneous and frequent contractions (duration of at least 40-50 seconds every 3 min), the next dose was not administered. If the patient did not enter into active labor (active labor: cervical dilatation of 3 to 5 cm or more in the presence of uterine contractions; latent phase: when the mother perceives regular contractions and usually ends at between 3 and 5 cm of dilatation (<xref rid="B19" ref-type="bibr">19</xref>)) 4-h after the last dose of misoprostol, she was diagnosed as failed induction and oxytocin infusion was used. All data were gathered prospectively and recorded. Maternal demographic characteristics (maternal age, gestational age, parity, mode of delivery, first Bishop Score, neonatal Apgar score) were recorded for two groups and then were compared. The indication for induction and important outcomes of labor were recorded for each patient. During intervention, each patient was assessed for possible outcomes. Tachysystole was defined as the presence of at least five uterine contractions in two consecutive 10-min periods. Hyperstimulation syndrome was defined as tachysystole and/or hypertonus on cardiotocography, with fetal heart rate (FHR) alterations such as bradycardia (FHR &#x0003c; b110 bpm), late decelerations, and or loss fetal heart rate variability. </p><p>
<italic>Outcomes Assay</italic>
</p><p>The primary outcome measure was the frequency of successful induction, defined as vaginal delivery within 24 h from the start of induction. Secondary outcomes included the rates of C/S due to fetal distress, time from first dose to active labor, induction-to delivery interval, duration of labor; number of misoprostol doses administered, and need for augmentation of labor with oxytocin. Neonatal outcomes included fetal heart rate (FHR) variation during labor, intrapartum meconium passage, intrapartum fetal death, and admission to the neonatal intensive care unit (NICU).</p><p>
<italic>Statistical analysis </italic>
</p><p>Analysis was performed with SPSS software (SPSS, Inc., Chicago, IL version 11.5), and then compared with &#x003c7;&#x000b2; test and Exact Fisher test for comparison of qualitative data. After check of normality, Mann-Whitney U test and Kruskal-Wallis test were used, if normality not fitted, Independent t-test and ANOVA test used if normality fitted to data. p-value less 0.05 was considered statistically significant.</p></sec><sec><title>Results and Discussion</title><p>A total of 140 women who admitted for termination of pregnancy were selected during the study procedure, 50 individuals received vaginal misoprostol and 90 cases attributed to the sublingual misoprostol group. </p><p>There was no significant difference in the demographic characteristics between two studied groups of women (<xref ref-type="table" rid="T1">Table 1</xref>). However the Bishop Score in the sublingual group was significantly higher than the vaginal group (P = 0.021). </p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Demographic characteristics of patients in both groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">
<bold>p-value</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>Vaginal Group</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>Sublingual Group</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>Item</bold>
</th></tr></thead><tfoot><tr><td align="left" rowspan="1" colspan="1">0.021</td><td align="left" rowspan="1" colspan="1">2.72&#x000b1;1.32</td><td align="left" rowspan="1" colspan="1">3.47&#x000b1;1.68</td><td align="left" rowspan="1" colspan="1">Bishop score</td></tr></tfoot><tbody><tr><td align="left" rowspan="1" colspan="1">0.67</td><td align="left" rowspan="1" colspan="1">24.34&#x000b1;4.05</td><td align="left" rowspan="1" colspan="1">24.65&#x000b1;4.42</td><td align="left" rowspan="1" colspan="1">Maternal Age( year)</td></tr><tr><td align="left" rowspan="1" colspan="1">0.20</td><td align="left" rowspan="1" colspan="1">1.36&#x000b1;.63</td><td align="left" rowspan="1" colspan="1">1.53&#x000b1;.86</td><td align="left" rowspan="1" colspan="1">Parity</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Indication for Induction</td></tr><tr><td align="left" rowspan="1" colspan="1">0.26</td><td align="left" rowspan="1" colspan="1">21(%42)</td><td align="left" rowspan="1" colspan="1">40(%43.5) </td><td align="left" rowspan="1" colspan="1"> Post term </td></tr><tr><td align="left" rowspan="1" colspan="1">0.82</td><td align="left" rowspan="1" colspan="1">5(%10)</td><td align="left" rowspan="1" colspan="1">6(%6.5)</td><td align="left" rowspan="1" colspan="1"> Oligihydraminios</td></tr><tr><td align="left" rowspan="1" colspan="1">0.15</td><td align="left" rowspan="1" colspan="1">18(%36)</td><td align="left" rowspan="1" colspan="1">29(%31.5)</td><td align="left" rowspan="1" colspan="1">PROM</td></tr><tr><td align="left" rowspan="1" colspan="1">0.66</td><td align="left" rowspan="1" colspan="1">1(%2)</td><td align="left" rowspan="1" colspan="1">1(%1.1)</td><td align="left" rowspan="1" colspan="1">Mild Preeclampsia</td></tr><tr><td align="left" rowspan="1" colspan="1">0.05</td><td align="left" rowspan="1" colspan="1">2 (%4)</td><td align="left" rowspan="1" colspan="1">0(%0)</td><td align="left" rowspan="1" colspan="1">Mild HTN</td></tr><tr><td align="left" rowspan="1" colspan="1">0.34</td><td align="left" rowspan="1" colspan="1">18(%36)</td><td align="left" rowspan="1" colspan="1">15(%17)</td><td align="left" rowspan="1" colspan="1">Loss motion</td></tr><tr><td align="left" rowspan="1" colspan="1">0.74</td><td align="left" rowspan="1" colspan="1">39.80&#x000b1;1.49</td><td align="left" rowspan="1" colspan="1">39.70&#x000b1;1.88</td><td align="left" rowspan="1" colspan="1">Gestational Age (weeks)</td></tr></tbody></table></table-wrap><p>The clinical outcomes of induction in both groups are summarized in <xref ref-type="table" rid="T2">Table 2</xref>. Our findings showed that there weren&#x02019;t any statistically significant differences between the number of administered doses of misoprostol every four hours (P &#x0003e; 0.05). Although the frequency of two doses were significantly higher than the other group (P = 0.43). About C/S indication, most of individuals showed absence of active labor from the sublingual group. </p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Clinical outcomes of induction in both groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">
<bold>p-value</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>Vaginal Group</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>Sublingual Group</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>Item</bold>
</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<bold>Number of doses</bold>
</th></tr></thead><tfoot><tr><td align="left" rowspan="1" colspan="1">0.43</td><td align="left" rowspan="1" colspan="1">2(%4)</td><td align="left" rowspan="1" colspan="1">3(%3.3)</td><td align="left" rowspan="1" colspan="1">Failure to progress</td></tr></tfoot><tbody><tr><td align="left" rowspan="1" colspan="1">0.22</td><td align="left" rowspan="1" colspan="1">25(%50)</td><td align="left" rowspan="1" colspan="1">41(%44.6)</td><td align="left" rowspan="1" colspan="1"> One dose</td></tr><tr><td align="left" rowspan="1" colspan="1">0.43</td><td align="left" rowspan="1" colspan="1">17(%34)</td><td align="left" rowspan="1" colspan="1">25(%27.2)</td><td align="left" rowspan="1" colspan="1"> Two dose</td></tr><tr><td align="left" rowspan="1" colspan="1">0.19</td><td align="left" rowspan="1" colspan="1">3(%6)</td><td align="left" rowspan="1" colspan="1">12(%13)</td><td align="left" rowspan="1" colspan="1"> Three dose </td></tr><tr><td align="left" rowspan="1" colspan="1">0.79</td><td align="left" rowspan="1" colspan="1">4(%8)</td><td align="left" rowspan="1" colspan="1">8(%8.7)</td><td align="left" rowspan="1" colspan="1"> Four dose</td></tr><tr><td align="left" rowspan="1" colspan="1">0.94</td><td align="left" rowspan="1" colspan="1">1(%2)</td><td align="left" rowspan="1" colspan="1">2(%2.2)</td><td align="left" rowspan="1" colspan="1"> Five dose</td></tr><tr><td align="left" rowspan="1" colspan="1">0.13</td><td align="left" rowspan="1" colspan="1">0(%0)</td><td align="left" rowspan="1" colspan="1">4(%4.3)</td><td align="left" rowspan="1" colspan="1"> Six dose`</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>Mode of delivery</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">0.60</td><td align="left" rowspan="1" colspan="1">45(%90)</td><td align="left" rowspan="1" colspan="1">78(%84.8)</td><td align="left" rowspan="1" colspan="1"> Vaginal</td></tr><tr><td align="left" rowspan="1" colspan="1">0.72</td><td align="left" rowspan="1" colspan="1">5(%10)</td><td align="left" rowspan="1" colspan="1">13(%14.1)</td><td align="left" rowspan="1" colspan="1"> CS</td></tr><tr><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0(%0)</td><td align="left" rowspan="1" colspan="1">1(%1.1)</td><td align="left" rowspan="1" colspan="1"> Vaccum</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>Indication for CS</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">0.53</td><td align="left" rowspan="1" colspan="1">2(%4)</td><td align="left" rowspan="1" colspan="1">4 (%4.3)</td><td align="left" rowspan="1" colspan="1"> Fetal distress</td></tr><tr><td align="left" rowspan="1" colspan="1">0.21</td><td align="left" rowspan="1" colspan="1">1(%2)</td><td align="left" rowspan="1" colspan="1">6(%6.5)</td><td align="left" rowspan="1" colspan="1">Absence of active labor</td></tr><tr><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0(%0)</td><td align="left" rowspan="1" colspan="1">0(%0)</td><td align="left" rowspan="1" colspan="1">Uterine over activity</td></tr></tbody></table></table-wrap><p>
<xref ref-type="table" rid="T3">Table 3</xref> compared the time and outcome delivery in vaginal and sublingual misoprostol group. There weren&#x02019;t any significant difference in passive and active phase and total time of delivery in two groups (P &#x0003e; 0.05). The maternal complication presentations included residue of placenta, tachysystole, vomiting, atoni and abdominal pain. Although there weren&#x02019;t any significant differences in two studied group (P &#x0003e; 0.05) but abdominal pain and vomiting were showed more in sublingual group than vaginal group. Also, the neonatal complications including meconial and prolaps weren&#x02019;t different between two studied groups (P &#x0003e; 0.05). </p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Compare time and outcome in vaginal and sublingual misoprostol in delivery</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">
<bold>p-value</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>Vaginal Group</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>Sublingual Group</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>Variables</bold>
</th></tr></thead><tfoot><tr><td align="left" rowspan="1" colspan="1">
<italic>0.46</italic>
</td><td align="left" rowspan="1" colspan="1">0(%0)</td><td align="left" rowspan="1" colspan="1">1(%1.1)</td><td align="left" rowspan="1" colspan="1">prolaps</td></tr></tfoot><tbody><tr><td align="left" rowspan="1" colspan="1">0.82</td><td align="left" rowspan="1" colspan="1">8.58&#x000b1;5.18</td><td align="left" rowspan="1" colspan="1">8.81&#x000b1;6.07</td><td align="left" rowspan="1" colspan="1">Passive phase of Delivery ( Hours)</td></tr><tr><td align="left" rowspan="1" colspan="1">0.95</td><td align="left" rowspan="1" colspan="1">2.87&#x000b1;1.72</td><td align="left" rowspan="1" colspan="1">2.89&#x000b1;1.90</td><td align="left" rowspan="1" colspan="1">Active phase of Delivery ( Hours)</td></tr><tr><td align="left" rowspan="1" colspan="1">0.61</td><td align="left" rowspan="1" colspan="1">11.08&#x000b1;3.41</td><td align="left" rowspan="1" colspan="1">11.62&#x000b1;6.76</td><td align="left" rowspan="1" colspan="1">Total time of Delivery ( Hours)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>Maternal Complication</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">0.87</td><td align="left" rowspan="1" colspan="1">1(%2)</td><td align="left" rowspan="1" colspan="1">2(%2.2)</td><td align="left" rowspan="1" colspan="1">Residue of Placenta</td></tr><tr><td align="left" rowspan="1" colspan="1">0.65</td><td align="left" rowspan="1" colspan="1">1(%2)</td><td align="left" rowspan="1" colspan="1">2(%2.2)</td><td align="left" rowspan="1" colspan="1"> Tachysystole</td></tr><tr><td align="left" rowspan="1" colspan="1">0.34</td><td align="left" rowspan="1" colspan="1">5(%10)</td><td align="left" rowspan="1" colspan="1">11(%12)</td><td align="left" rowspan="1" colspan="1"> Vomiting</td></tr><tr><td align="left" rowspan="1" colspan="1">0.09</td><td align="left" rowspan="1" colspan="1">3(%6)</td><td align="left" rowspan="1" colspan="1">3(%3.3)</td><td align="left" rowspan="1" colspan="1"> Atoni</td></tr><tr><td align="left" rowspan="1" colspan="1">0.23</td><td align="left" rowspan="1" colspan="1">1(%2)</td><td align="left" rowspan="1" colspan="1">5(%5.5)</td><td align="left" rowspan="1" colspan="1"> Abdominal Pain</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>Neonatal complication</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>1.00</italic>
</td><td align="left" rowspan="1" colspan="1">3(%6)</td><td align="left" rowspan="1" colspan="1">5(%5.5)</td><td align="left" rowspan="1" colspan="1">Meconial</td></tr></tbody></table></table-wrap><p>The results of the present study showed that sublingual misoprostol is effective as vaginal misoprostol for induction of labor with live term fetuses. </p><p>Previous studies had already promised the beneficial effects of pharmacological over mechanical cervical ripening (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>). Previous studies showed that Misoprostol is an effective agent by oral, vaginal and sublingual administration for induction of labor before surgical termination of pregnancy. In our study, the vaginal and sublingual misoprostol weren&#x02019;t associated with significant differences in the number of women in aspect of clinical outcomes and the maternal and neonatal complication. A randomized controlled trial evaluated the vaginal and sublingual misoprostol for second trimester abortion (<xref rid="B22" ref-type="bibr">22</xref>). They showed that a higher effectiveness of sublingual administration, but fever was more common in vaginal consumption (<xref rid="B22" ref-type="bibr">22</xref>). We didn&#x02019;t evaluate these two methods in second trimester, but we found no significant difference among the maternal complication in studied period. Saxena <italic>et al</italic>. evaluated the sublingual versus vaginal routes of misoprostol in the first trimester abortions. They concluded that the sublingual form is more effective and convenient than vaginal forms for cervical dilatation (<xref rid="B23" ref-type="bibr">23</xref>). </p><p>Different routes of misoprostol have been administrated for cervical priming (<xref rid="B24" ref-type="bibr">24</xref>-<xref rid="B28" ref-type="bibr">28</xref>). Both oral and vaginal forms seem to be equally effective (<xref rid="B29" ref-type="bibr">29</xref>). However, some women found the vaginal forms inconvenient and unacceptable (<xref rid="B30" ref-type="bibr">30</xref>). Tang <italic>et al</italic>. (2004) compared sublingual and vaginal misoprostol for preoperative cervical priming, prior to surgical termination and found similar preoperative side-effects within groups (<xref rid="B31" ref-type="bibr">31</xref>). However, sublingual misoprostol has the advantages like being more convenient to administer. We found both sublingual and vaginal misoprostol similarly effective in cervical priming. </p><p>Zahran <italic>et al</italic>. (2009) like our study, evaluated sublingual versus vaginal misoprostol for induction of labor at term, but in randomized prospective placebo controlled study (<xref rid="B32" ref-type="bibr">32</xref>). We found similar results like Zahran <italic>et al</italic> study as fetal distress in both group had the highest frequency, but there was no difference between groups in case of induction to delivery interval, duration of labor, neonatal outcome or maternal side effects. However in comparison to their study (<xref rid="B32" ref-type="bibr">32</xref>), we found low number of attributed labors that had meconium staining in both studied groups, but less active labor in sublingual group.</p><p>They found sublingual route promised to higher patient&#x02019;s satisfaction level (31). Although we didn&#x02019;t evaluate the patient satisfaction level but our results, confirmed the previous studies results in other criterion.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>We concluded that sublingual misoprostol seems as effective as vaginal misoprostol for induction of labor at term. Furthermore misoprostol sublingual routes poses some advantages like convenient to administer and might be more suitable than vaginal form. </p></sec></body><back><ack><title>Acknowledgements</title><p>This study has been financially supported by Medical Faculty of Mashhad University of Medical Sciences. The authors would like to thank Mrs Tooran Makhdoumi for edition of this paper.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riskin-Mashiah</surname><given-names>S</given-names></name><name><surname>Wilkins</surname><given-names>I</given-names></name></person-group><article-title>Cervical ripening</article-title><source>Obstet Gynecol Clin. North Am</source><year>1999</year><volume>26</volume><fpage>243</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">10399759</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Laws</surname><given-names>PJ</given-names></name><name><surname>Sullivan</surname><given-names>EA</given-names></name></person-group><source>Australia&#x02019;s mothers and babies 2002</source><year>2004</year><publisher-loc>Sydney</publisher-loc><publisher-name>Australian Institute of Health and Welfare (AIHW), National Perinatal Statistics Unit (NPSU)</publisher-name></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirteimouri</surname><given-names>M</given-names></name><name><surname>Tara</surname><given-names>F</given-names></name><name><surname>Teimouri</surname><given-names>B</given-names></name><name><surname>Sakhavar</surname><given-names>N</given-names></name><name><surname>Vaezi</surname><given-names>A</given-names></name></person-group><article-title>Efficacy of Rectal Misoprostol for Prevention of Postpartum Hemorrhage</article-title><source> Iran J. Pharm. Res. </source><year>2012</year><volume>12</volume><fpage>469</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">24250623</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feitosa</surname><given-names>FE</given-names></name><name><surname>Sampaio</surname><given-names>ZS</given-names></name><name><surname>Alencar</surname><given-names>CA Jr</given-names></name><name><surname>Amorim</surname><given-names>MM</given-names></name><name><surname>Passini</surname><given-names>R Jr</given-names></name></person-group><article-title>Sublingual vs vaginal misoprostol for induction of labor</article-title><source> Int J. Gynaecol Obstet. </source><year>2006</year><volume>94</volume><fpage>91</fpage><pub-id pub-id-type="pmid">16828095</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartusevicius</surname><given-names>A</given-names></name><name><surname>Barcaite</surname><given-names>E</given-names></name><name><surname>Krikstolaitis</surname><given-names>R</given-names></name><name><surname>Gintautas</surname><given-names>V</given-names></name><name><surname>Nadisauskiene</surname><given-names>R</given-names></name></person-group><article-title>Sublingual compared with vaginal misoprostol for labour induction at term: A randomised controlled trial</article-title><source> BJOG</source><year>2006</year><volume>113</volume><fpage>1431</fpage><pub-id pub-id-type="pmid">17083652</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shetty</surname><given-names>A</given-names></name><name><surname>Danielian</surname><given-names>P</given-names></name><name><surname>Templeton</surname><given-names>A</given-names></name></person-group><article-title>Sublingual misoprostol for the induction of labor at term</article-title><source> Am J. Obstet Gynecol.</source><year>2002</year><volume>186</volume><fpage>72</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">11810088</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shetty</surname><given-names>A</given-names></name><name><surname>Mackie</surname><given-names>L</given-names></name><name><surname>Danielian</surname><given-names>P</given-names></name><name><surname>Rice</surname><given-names>P</given-names></name><name><surname>Templeton</surname><given-names>A</given-names></name></person-group><article-title>Sublingual compared with oral misoprostol in term labour induction: A randomised controlled trial</article-title><source> BJOG</source><year>2002</year><volume>109</volume><fpage>645</fpage><lpage>650</lpage><pub-id pub-id-type="pmid">12118642</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="book"><collab>Royal College of Obstetricians and Gynecologists</collab><article-title>Induction of labour: Evidence-based</article-title><date-in-citation>Cited 2 June 2001</date-in-citation><publisher-loc> London, England</publisher-loc><publisher-name>RCOG Clinical Effectiveness Support Unit</publisher-name><comment>Available from:URL: <ext-link ext-link-type="uri" xlink:href="http://www.rcog.uk/resources/public/rcog_induction_of_labour.pdf">http://www.rcog.uk/resources/public/rcog_induction_of_labour.pdf</ext-link></comment></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caliskan</surname><given-names>E</given-names></name><name><surname>Bodur</surname><given-names>H</given-names></name><name><surname>Ozeren</surname><given-names>S</given-names></name><name><surname>Corakci</surname><given-names>A</given-names></name><name><surname>Ozkan</surname><given-names>S</given-names></name><name><surname>Yucesoy</surname><given-names>I</given-names></name></person-group><article-title>Misoprostol 50 Ag sublingually versus vaginally for labor induction at term</article-title><source> Gynecol Obstet. Invest.</source><year>2005</year><volume>59</volume><fpage>155</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">15640607</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moraes-Filho</surname><given-names>OB</given-names></name><name><surname>Albuquerque</surname><given-names>RM</given-names></name><name><surname>Pacheco</surname><given-names>AJC</given-names></name><name><surname>Ribeiro</surname><given-names>RH</given-names></name><name><surname>Cecatti</surname><given-names>JG</given-names></name><name><surname>Welkovic</surname><given-names>S</given-names></name></person-group><article-title>Sublingual versus vaginal misoprostol for labor induction of term pregnancies</article-title><source> Rev Bras. Ginecol Obstet.</source><year>2005</year><volume> 27</volume><fpage>20</fpage><lpage>23</lpage></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alfirevic</surname><given-names>Z</given-names></name><name><surname>Weeks</surname><given-names>A</given-names></name></person-group><article-title>Oral misoprostol for induction of labour</article-title><source> Cochrane Database Sys Rev. </source><volume>2</volume><fpage>1338</fpage></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biglar</surname><given-names>M</given-names></name><name><surname>Soltani</surname><given-names>K</given-names></name><name><surname>Nabati</surname><given-names>F</given-names></name><name><surname>Bazl</surname><given-names>R</given-names></name><name><surname>Mojab</surname><given-names>F</given-names></name><name><surname>Amanlou</surname><given-names>M</given-names></name></person-group><article-title>A Preliminary Investigation of the Jack-Bean Urease Inhibition by Randomly Selected Traditionally Used Herbal Medicine</article-title><source> Iran J. Pharm. Res.</source><year>2012</year><volume>11</volume><fpage>831</fpage><lpage>837</lpage><pub-id pub-id-type="pmid">24250509</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>JB</given-names></name><name><surname>Thigpen</surname><given-names>BD</given-names></name><name><surname>Bofill</surname><given-names>JA</given-names></name><name><surname>Magann</surname><given-names>E</given-names></name><name><surname>Moore</surname><given-names>LE</given-names></name><name><surname>Martin</surname><given-names>JN Jr</given-names></name></person-group><article-title>A randomized clinical trial comparing vaginal misoprostol versus cervical foley plus oral misoprostol for cervical ripening and labor induction</article-title><source> Am J. Perinatol. </source><year>2009</year><volume>26</volume><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">18850516</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shetty</surname><given-names>A</given-names></name><name><surname>Danielian</surname><given-names>P</given-names></name><name><surname>Templeton</surname><given-names>A</given-names></name></person-group><article-title>Sublingual misoprostol for the induction of labor at term</article-title><source> Am J. Obstet Gynecol. </source><year>2002</year><volume>186</volume><fpage>72</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">11810088</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wing</surname><given-names>DA</given-names></name><name><surname>Ham</surname><given-names>D</given-names></name><name><surname>Paul</surname><given-names>RH</given-names></name></person-group><article-title>A comparison of orally administered misoprostol with vaginally administered misoprostol for cervical ripening and labor induction</article-title><source> Am J. Obstet Gyncol. </source><year>1999</year><volume>180</volume><fpage>1155</fpage><lpage>1160</lpage></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fakoor</surname><given-names>F</given-names></name><name><surname>Mirzaei</surname><given-names>M</given-names></name><name><surname>Naghipoor</surname><given-names>MR</given-names></name><name><surname>Ebrahimi</surname><given-names>H</given-names></name><name><surname>Mahdavi</surname><given-names>M</given-names></name></person-group><article-title>Comparison between Sublingual Misoprostol and Intravenous Oxytocin in Management of Third Stage of Labor</article-title><source> Iran J. Obst. Gynecol. Inferti. </source><year>2013</year><volume>15</volume><fpage>7</fpage><lpage>14</lpage></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muzonzini</surname><given-names>G</given-names></name><name><surname>Hofmeyr</surname><given-names>GJ</given-names></name></person-group><article-title>Buccal or sublingual misoprostol for cervical ripening and induction of labour</article-title><source> Cochrane Database Sys Rev. </source><year>2004</year><volume>18</volume><fpage>4221</fpage></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cuninngham</surname><given-names>FG</given-names></name><name><surname>Leveno</surname><given-names>KJ</given-names></name><name><surname>Bloom</surname><given-names>SL</given-names></name><name><surname>Hauth</surname><given-names>JC</given-names></name><name><surname>Rouse</surname><given-names>DJ</given-names></name><name><surname>Spong</surname><given-names>CY</given-names></name></person-group><source>Williams Obstetrics</source><year>2010</year><edition>23rd ed. </edition><publisher-loc>New York</publisher-loc><publisher-name>McGrow-Hill </publisher-name><fpage>503</fpage></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cuninngham</surname><given-names>FG</given-names></name><name><surname>Leveno</surname><given-names>KJ</given-names></name><name><surname>Bloom</surname><given-names>SL</given-names></name><name><surname>Hauth</surname><given-names>JC</given-names></name><name><surname>Rouse</surname><given-names>DJ</given-names></name><name><surname>Spong</surname><given-names>CY</given-names></name></person-group><source>Williams Obstetrics</source><year>2010</year><edition>23rd ed. </edition><publisher-loc>New York</publisher-loc><publisher-name>McGrow-Hill</publisher-name><fpage>386</fpage><lpage>388</lpage></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schutz</surname><given-names>KF</given-names></name><name><surname>Grimes</surname><given-names>DA</given-names></name><name><surname>Cabes</surname><given-names>WJ</given-names></name></person-group><article-title>Measures to prevent cervical injury during suction curettage abortion</article-title><source> Lancet</source><year>1983</year><volume>1</volume><fpage>1182</fpage><lpage>1184</lpage><pub-id pub-id-type="pmid">6133988</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gimes</surname><given-names>DA</given-names></name><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Cates</surname><given-names>WJ</given-names></name></person-group><article-title>Prevention of uterine perforation during curettage abortion</article-title><source> JAMA</source><year>1984</year><volume>251</volume><fpage>2108</fpage><lpage>2111</lpage><pub-id pub-id-type="pmid">6708260</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von</surname><given-names>Hertzen H</given-names></name><name><surname>Piaggio</surname><given-names>G</given-names></name><name><surname>Wojdyla</surname><given-names>D</given-names></name><name><surname>Nguyen</surname><given-names>TM</given-names></name><name><surname>Marions</surname><given-names>L</given-names></name><name><surname>Okoev</surname><given-names>G</given-names></name><name><surname>Khomassuridze</surname><given-names>A</given-names></name><name><surname>Kereszturi</surname><given-names>A</given-names></name><name><surname>Mittal</surname><given-names>S</given-names></name><name><surname>Nair</surname><given-names>R</given-names></name><name><surname>Daver</surname><given-names>R</given-names></name><name><surname>Pretnar-Darovec</surname><given-names>A</given-names></name><name><surname>Dickson</surname><given-names>K</given-names></name><name><surname>Nguyen</surname><given-names>DH</given-names></name><name><surname>Nguyen</surname><given-names>HB</given-names></name><name><surname>Hoang</surname><given-names>TD</given-names></name><name><surname>Peregoudov</surname><given-names>A</given-names></name></person-group><article-title>WHO Research Group on Post-ovulatory Methods of Fertility Regulation. Comparison of vaginal and sublingual misoprostol for second trimester abortion: randomized controlled equivalence trial</article-title><source>Hum Reprod</source><year>2009</year><volume>24</volume><fpage>106</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">18794161</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxena</surname><given-names>P</given-names></name><name><surname>Salhan</surname><given-names>S</given-names></name><name><surname>Sarda</surname><given-names>N</given-names></name></person-group><article-title>Sublingual versus vaginal route of misoprostol for cervical ripening prior to surgical termination of first trimester abortions</article-title><source> Eur J. Obstet Gynecol Reprod Biol. </source><year>2006</year><volume>125</volume><fpage>109</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">16139942</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>SP</given-names></name><name><surname>Fang</surname><given-names>AH</given-names></name><name><surname>Chen</surname><given-names>QF</given-names></name><name><surname>Huang</surname><given-names>YM</given-names></name><name><surname>Chen</surname><given-names>OJ</given-names></name><name><surname>Cheng</surname><given-names>LN</given-names></name></person-group><article-title>Termination of second-trimester pregnancy by mifepristone combined with misoprostol versus intra-amniotic injection of ethacridine lactate (Rivanol&#x000ae;): a systematic review of Chinese trials</article-title><source> Contraception</source><year>2011</year><volume>84</volume><fpage>214</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">21843683</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>QJ</given-names></name><name><surname>Hou</surname><given-names>SP</given-names></name><name><surname>Meads</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>YM</given-names></name><name><surname>Hong</surname><given-names>QQ</given-names></name><name><surname>Zhu</surname><given-names>HP</given-names></name><name><surname>Cheng</surname><given-names>LN</given-names></name></person-group><article-title>EBM-CONNECT Collaboration. Mifepristone in combination with prostaglandins for termination of 10-16 weeks&#x0203a; gestation: a systematic review</article-title><source>Eur. J. Obstet. Gynecol. Reprod Biol. </source><volume> 159</volume><fpage>247</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">21741747</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Fang</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name></person-group><article-title>One- and two-day mifepristone-misoprostol intervals for second trimester termination of pregnancy between 13 and 16 weeks of gestation</article-title><source> Int J. Gynaecol. Obstet.</source><year>2010</year><volume>111</volume><fpage>126</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">20705290</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>SC</given-names></name><name><surname>Kapp</surname><given-names>N</given-names></name><name><surname>Vragpvoc</surname><given-names>O</given-names></name><name><surname>Borgata</surname><given-names>L</given-names></name></person-group><article-title>Randomized trial of buccal versus vaginal misoprostol for induction of second trimester abortion</article-title><source> Contraception</source><year>2010</year><volume>81</volume><fpage>441</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">20399952</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodd</surname><given-names>JM</given-names></name><name><surname>Crowther</surname><given-names>CA</given-names></name></person-group><article-title>Misoprostol for induction of labour to terminate pregnancy in the second or third trimester for women with a fetal anomaly or after intrauterine fetal death</article-title><source> Cochrane Database Syst Rev. </source><year>2010</year><fpage>4901</fpage></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngai</surname><given-names>SW</given-names></name><name><surname>Chan</surname><given-names>YM</given-names></name><name><surname>Tang</surname><given-names>OS</given-names></name><name><surname>Ho</surname><given-names>PC</given-names></name></person-group><article-title>The use of misoprostol for pre-operative cervical dilatation prior to vacuum aspiration: a randomized trial</article-title><source> Hum Reprod. </source><year>1999</year><volume>14</volume><fpage>2139</fpage><lpage>2142</lpage><pub-id pub-id-type="pmid">10438440</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>PC</given-names></name><name><surname>Ngai</surname><given-names>SW</given-names></name><name><surname>Liu</surname><given-names>KL</given-names></name><name><surname>Wong</surname><given-names>GC</given-names></name><name><surname>Lee</surname><given-names>SW</given-names></name></person-group><article-title>Vaginal misoprostol compared with oral misoprostol in termination of second trimester pregnancy</article-title><source> Obstet Gynecol. </source><year>1997</year><volume>90</volume><fpage>735</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">9351755</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>OS</given-names></name><name><surname>Mok</surname><given-names>KH</given-names></name><name><surname>Ho</surname><given-names>PC</given-names></name></person-group><article-title>A randomized study comparing the use of sublingual to vaginal misoprostol for pre-operative cervical priming prior to surgical termination of pregnancy in the first trimester</article-title><source> Hum Reprod. </source><year>2004</year><volume>19</volume><fpage>1101</fpage><lpage>1104</lpage><pub-id pub-id-type="pmid">15070888</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zahran</surname><given-names>KM</given-names></name><name><surname>Shahin</surname><given-names>AY</given-names></name><name><surname>Abdellah</surname><given-names>MS</given-names></name><name><surname>Elsayh</surname><given-names>KI</given-names></name></person-group><article-title>Sublingual versus vaginal misoprostol for induction of labor at term: a randomized prospective placebo-controlled study</article-title><source> J Obstet. Gynaecol. Res.</source><year>2009</year><volume> 35</volume><fpage>1054</fpage><lpage>1060</lpage><pub-id pub-id-type="pmid">20144171</pub-id></element-citation></ref></ref-list></back></article>